Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Both as oral monotherapy and in combination with cetuximab, adagrasib exhibited antitumor activity in patients who had received prior treatment and had metastatic colorectal cancer with mutant KRAS G12C. In the group receiving combination therapy, the median response time was greater than 6 months. Reversible negative outcomes were frequent in both groups.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form